758 related articles for article (PubMed ID: 31439591)
1. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
2. Progranulin Promotes Bleomycin-Induced Skin Sclerosis by Enhancing Transforming Growth Factor-β/Smad3 Signaling through Up-Regulation of Transforming Growth Factor-β Type I Receptor.
Yang T; Zhang X; Chen A; Xiao Y; Sun S; Yan J; Cao Y; Chen J; Li F; Zhang Q; Huang K
Am J Pathol; 2019 Aug; 189(8):1582-1593. PubMed ID: 31108104
[TBL] [Abstract][Full Text] [Related]
3. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S
Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851
[TBL] [Abstract][Full Text] [Related]
4. Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis.
Tomcik M; Palumbo-Zerr K; Zerr P; Sumova B; Avouac J; Dees C; Distler A; Becvar R; Distler O; Schett G; Senolt L; Distler JH
Ann Rheum Dis; 2016 Mar; 75(3):609-16. PubMed ID: 25603829
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.
Zhang Y; Pötter S; Chen CW; Liang R; Gelse K; Ludolph I; Horch RE; Distler O; Schett G; Distler JHW; Dees C
Ann Rheum Dis; 2018 May; 77(5):744-751. PubMed ID: 29431122
[TBL] [Abstract][Full Text] [Related]
6. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
[TBL] [Abstract][Full Text] [Related]
7. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.
Liang R; Šumová B; Cordazzo C; Mallano T; Zhang Y; Wohlfahrt T; Dees C; Ramming A; Krasowska D; Michalska-Jakubus M; Distler O; Schett G; Šenolt L; Distler JH
Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816
[TBL] [Abstract][Full Text] [Related]
8. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.
Lakos G; Takagawa S; Chen SJ; Ferreira AM; Han G; Masuda K; Wang XJ; DiPietro LA; Varga J
Am J Pathol; 2004 Jul; 165(1):203-17. PubMed ID: 15215176
[TBL] [Abstract][Full Text] [Related]
9. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
[TBL] [Abstract][Full Text] [Related]
11. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
[TBL] [Abstract][Full Text] [Related]
13. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.
Tomcik M; Palumbo-Zerr K; Zerr P; Avouac J; Dees C; Sumova B; Distler A; Beyer C; Cerezo LA; Becvar R; Distler O; Grigorian M; Schett G; Senolt L; Distler JH
Ann Rheum Dis; 2015 Sep; 74(9):1748-55. PubMed ID: 24709861
[TBL] [Abstract][Full Text] [Related]
14. Extracellular SPARC cooperates with TGF-β signalling to induce pro-fibrotic activation of systemic sclerosis patient dermal fibroblasts.
Carvalheiro T; Malvar Fernández B; Ottria A; Giovannone B; Marut W; Reedquist KA; Garcia S; Radstake TR
Rheumatology (Oxford); 2020 Sep; 59(9):2258-2263. PubMed ID: 31840182
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
[TBL] [Abstract][Full Text] [Related]
17. Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.
Zerr P; Palumbo-Zerr K; Huang J; Tomcik M; Sumova B; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2016 Jan; 75(1):226-33. PubMed ID: 25180292
[TBL] [Abstract][Full Text] [Related]
18. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis.
Takahashi T; Asano Y; Ichimura Y; Toyama T; Taniguchi T; Noda S; Akamata K; Tada Y; Sugaya M; Kadono T; Sato S
Arthritis Rheumatol; 2015 Jan; 67(1):254-65. PubMed ID: 25302613
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis.
Del Galdo F; Sotgia F; de Almeida CJ; Jasmin JF; Musick M; Lisanti MP; Jiménez SA
Arthritis Rheum; 2008 Sep; 58(9):2854-65. PubMed ID: 18759267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
